SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 12.8% Stake in Seres Therapeutics

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming their beneficial ownership of 12.8% of Seres Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 21,811,697 shares of Seres Therapeutics Inc. common stock.
• This aggregate amount represents 12.8% of the total outstanding common stock of Seres Therapeutics Inc.
• The ownership snapshot date for this filing is December 31, 2024.
• FMR LLC holds sole voting and sole dispositive power over all 21,811,697 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is also deemed to beneficially own these shares with sole dispositive power.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Fidelity Growth Company Commingled Pool is noted to have an interest in 9,702,826 shares, representing 5.7% of the total outstanding common stock, as of December 31, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership. It does not contain operational, financial performance, or strategic updates that would typically influence sentiment positively or negatively, thus it is neutral.

Positives

• The continued significant stake by a major institutional investor like FMR LLC indicates ongoing confidence or a long-term investment strategy in Seres Therapeutics.
• Transparency provided by the Schedule 13G filing offers clarity to the market regarding major ownership positions.

Future Outlook

NA

Industry Context

This filing is a standard disclosure for a publicly traded biotechnology company, indicating a significant passive investment by a large asset management firm. Such institutional holdings are common across the biotech sector, reflecting investor interest in companies with potential for therapeutic innovation.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can be a factor in assessing investor confidence and liquidity.

Key Dates

Keywords

Seres Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investor, biotechnology, pharmaceuticals